美国食品和药物管理局批准Minimar心脏支架用于患有先天性心脏缺陷的婴儿和幼儿. FDA approves Minima heart stent for infants and young children with congenital heart defects.

美国食品和药物管理局批准了Minim心脏支架用于婴儿和幼儿, 旨在治疗先天性心脏缺陷, 并减少多次心脏手术的需要. The FDA has approved the Minima heart stent for infants and young children, designed to treat congenital heart defects and reduce the need for multiple open-heart surgeries. 每年约有4万个美国婴儿出生时有这种缺陷。 Annually, about 40,000 U.S. babies are born with such defects. 与传统支架不同,Minimastent随着孩子的成长而成长,可以通过微创手术进行调整,允许在医院停留时间更短,通常只需一天,而手术需要一周. Unlike traditional stents, the Minima stent grows with the child and can be adjusted through a minimally invasive procedure, allowing for shorter hospital stays—typically just one day compared to a week for surgery.